Welcome to our dedicated page for Rezolute SEC filings (Ticker: RZLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rezolute, Inc. filings document regulatory disclosures for a Nasdaq-listed Nevada biopharmaceutical company developing ersodetug for hyperinsulinism. Recent Current Reports on Form 8-K include Regulation FD disclosures on the sunRIZE congenital hyperinsulinism program, FDA meeting updates, investor presentations, expanded access data in tumor hyperinsulinism, and exhibits containing related press releases and corporate materials.
The filing record also includes Form 8-K disclosures for quarterly financial results, annual stockholder voting matters, board elections and amendments to executive employment agreements. These documents record the company’s clinical-development communications, governance actions, capital-market disclosures and material corporate agreements.
Rezolute, Inc. filed an Form 8-K reporting a material corporate event under Item 5.02: the election or appointment of a Chief Commercial Officer. The filing references a press release dated August 20, 2025 and is signed by Chief Executive Officer Nevan Charles Elam. The submission also includes standard cover and interactive data references for the Inline XBRL document and cites communications rules for solicitations and pre-commencement communications under the Securities Act and Exchange Act.
The filing provides notice of an executive appointment but does not disclose the appointee's name, compensation, start date, or other background details within the provided text. No financial tables, transactions, or earnings data are included in the excerpt supplied.
Insider Trading Alert: Brian Kenneth Roberts, Chief Medical Officer of Rezolute (RZLT), has acquired 2,500 common shares at a weighted average price of $4.3756 per share on June 25, 2025. The transaction was executed through multiple purchases ranging from $4.37 to $4.38 per share.
Following this transaction, Roberts' holdings include:
- Direct ownership: 172,852 common shares (15,500 + 157,352 from previous holdings)
- Indirect ownership: 1,376 shares held by minor child
This insider purchase demonstrates continued confidence in the company by a key executive. The Form 4 filing was completed within the required reporting timeframe, with the transaction executed on June 25, 2025, and reported on June 28, 2025.
Filing overview: On 24 June 2025, Rezolute, Inc. (ticker RZLT) submitted a Form 4 disclosing a change in beneficial ownership by its Chief Financial Officer, Daron Evans.
Transaction details: Mr. Evans executed an open-market purchase (transaction code “P”) of 5,000 common shares at $4.05 per share on the reported date. No sales or other derivative transactions were listed.
Post-transaction holdings: After the purchase, the CFO directly holds 268,900 shares. He also reports indirect ownership of 23,000 shares for minor child #1, 20,000 shares held by his spouse, 4,500 shares each for minor children #2 and #3, and 40,000 shares through PoC Capital LLC, a California entity he manages. Combined, these positions represent 360,900 common shares. The filing states that Evans disclaims beneficial ownership of PoC Capital shares except for his pecuniary interest.
The Form 4 was electronically signed by Daron Evans on 24 June 2025.
Form 4 overview: Rezolute, Inc. (RZLT) disclosed that director Young-Jin Kim executed a substantial open-market purchase of the company’s common stock on 13 June 2025.
- Transaction code P (Purchase): 1,230,769 common shares acquired indirectly through Handok, Inc. at $3.25 per share, implying a cash outlay of roughly $4.0 million.
- Post-transaction holdings: Handok, Inc. now holds 8,423,386 shares (indirect ownership attributed to Kim). Kim also continues to hold 149,950 shares directly; no change was reported for the direct position.
- The filing states that Kim “disclaims beneficial ownership” of Handok’s holdings except to the extent of any pecuniary interest, but SEC rules still require attribution because he is a director of Rezolute and a control person at Handok.
Investment take-aways:
- A multi-million-dollar insider purchase often signals personal or strategic confidence in Rezolute’s pipeline and valuation.
- The purchase increases Handok’s stake and may strengthen the strategic relationship between the two companies, as Handok has historically been a significant investor and commercial partner.
- No derivative transactions, sales, or option exercises were reported, underscoring a purely additive position.
The Form 4 contains no earnings metrics, operational updates or forward-looking statements; the filing is limited to reporting the insider trade required under Section 16(a).
Rezolute, Inc. (RZLT) – Form 4 insider transaction
Director Nerissa Kreher reported purchasing 3,076 common shares of Rezolute on 13 June 2025 at an average price of $3.25 per share. Following the transaction, Dr. Kreher directly owns 37,576 shares of the company’s common stock. No derivative securities were involved, and no dispositions were reported.